Format

Send to

Choose Destination
Breast Cancer Res. 2019 Jan 22;21(1):9. doi: 10.1186/s13058-018-1092-x.

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.

Author information

1
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, NO-0379, Oslo, Norway. ketilcamilio@gmail.com.
2
Lytix Biopharma AS, Hoffsveien 4, NO-0275, Oslo, Norway. ketilcamilio@gmail.com.
3
Oslo Cancer Cluster Incubator, Ullernchausseen 64/66, 0379, Oslo, Norway. ketilcamilio@gmail.com.
4
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, NO-0379, Oslo, Norway.
5
Lytix Biopharma AS, Hoffsveien 4, NO-0275, Oslo, Norway.
6
Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, NO-0372, Oslo, Norway.
7
Institute of Clinical Medicine, University of Oslo, NO-0372, Oslo, Norway.
8
Department of Cellular Therapy, Oslo University Hospital, NO-0379, Oslo, Norway.
9
Department of Medical Biology, The Arctic University of Norway, NO-9037, Tromsø, Norway.

Abstract

BACKGROUND:

Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor microenvironment, turning "cold" tumors "hot" through a significant increase in tumor-infiltrating lymphocytes.

METHODS:

We investigated the potential of LTX-315 to be used in combination with standard-of-care chemotherapy (doxorubicin, brand name CAELYX®) against triple-negative breast cancer in an orthotopic 4 T1 mammary fat pad model. Tumor growth curves were compared using one-way ANOVA analysis of variance and Tukey's multiple comparisons test, and animal survival curves were compared using the log-rank (Mantel-Cox) test. We considered p values ≤0.05 to indicate statistical significance.

RESULTS:

We found that LTX-315 displayed a strong additive antitumoral effect when used in combination with CAELYX®, and induced immune-mediated changes in the tumor microenvironment, followed by complete regression in the majority of animals treated. Furthermore, imaging techniques and histological examination showed that the combination induced strong local necrosis, followed by an increase in the infiltration of CD4+ and CD8+ immune cells into the tumor parenchymal tissue.

CONCLUSIONS:

Our data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the treatment of triple-negative breast cancer.

KEYWORDS:

Combination therapy; DAMPs; Doxorubicin; ICD; Immunochemotherapy; Immunotherapy; LTX-315; Oncolytic peptide; Triple-negative breast cancer

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center